Literature DB >> 8760814

Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy.

D S Chao1, J R Gorospe, J E Brenman, J A Rafael, M F Peters, S C Froehner, E P Hoffman, J S Chamberlain, D S Bredt.   

Abstract

Becker muscular dystrophy is an X-linked disease due to mutations of the dystrophin gene. We now show that neuronal-type nitric oxide synthase (nNOS), an identified enzyme in the dystrophin complex, is uniquely absent from skeletal muscle plasma membrane in many human Becker patients and in mouse models of dystrophinopathy. An NH2-terminal domain of nNOS directly interacts with alpha 1-syntrophin but not with other proteins in the dystrophin complex analyzed. However, nNOS does not associate with alpha 1-syntrophin on the sarcolemma in transgenic mdx mice expressing truncated dystrophin proteins. This suggests a ternary interaction of nNOS, alpha 1-syntrophin, and the central domain of dystrophin in vivo, a conclusion supported by developmental studies in muscle. These data indicate that proper assembly of the dystrophin complex is dependent upon the structure of the central rodlike domain and have implications for the design of dystrophin-containing vectors for gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760814      PMCID: PMC2192729          DOI: 10.1084/jem.184.2.609

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains.

Authors:  J E Brenman; D S Chao; S H Gee; A W McGee; S E Craven; D R Santillano; Z Wu; F Huang; H Xia; M F Peters; S C Froehner; D S Bredt
Journal:  Cell       Date:  1996-03-08       Impact factor: 41.582

2.  Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses.

Authors:  K Arahata; E P Hoffman; L M Kunkel; S Ishiura; T Tsukahara; T Ishihara; N Sunohara; I Nonaka; E Ozawa; H Sugita
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Somatic reversion/suppression of the mouse mdx phenotype in vivo.

Authors:  E P Hoffman; J E Morgan; S C Watkins; T A Partridge
Journal:  J Neurol Sci       Date:  1990-10       Impact factor: 3.181

4.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle.

Authors:  J M Ervasti; K Ohlendieck; S D Kahl; M G Gaver; K P Campbell
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

5.  Purification of dystrophin from skeletal muscle.

Authors:  J M Ervasti; S D Kahl; K P Campbell
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

6.  Localization of nitric oxide synthase indicating a neural role for nitric oxide.

Authors:  D S Bredt; P M Hwang; S H Snyder
Journal:  Nature       Date:  1990-10-25       Impact factor: 49.962

7.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.

Authors:  M Koenig; A P Monaco; L M Kunkel
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

8.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.

Authors:  E P Hoffman; K H Fischbeck; R H Brown; M Johnson; R Medori; J D Loike; J B Harris; R Waterston; M Brooke; L Specht
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

9.  Improved diagnosis of Becker muscular dystrophy by dystrophin testing.

Authors:  E P Hoffman; L M Kunkel; C Angelini; A Clarke; M Johnson; J B Harris
Journal:  Neurology       Date:  1989-08       Impact factor: 9.910

10.  Syntrophin binds to an alternatively spliced exon of dystrophin.

Authors:  A H Ahn; L M Kunkel
Journal:  J Cell Biol       Date:  1995-02       Impact factor: 10.539

View more
  46 in total

Review 1.  Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse.

Authors:  J M Gillis
Journal:  J Muscle Res Cell Motil       Date:  1999-10       Impact factor: 2.698

Review 2.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  There's NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling.

Authors:  Pavel I Nedvetsky; William C Sessa; Harald H H W Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

Review 4.  Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.

Authors:  Younghye Moon; Jordan E Balke; Derik Madorma; Michael P Siegel; Gary Knowels; Peter Brouckaert; Emmanuel S Buys; David J Marcinek; Justin M Percival
Journal:  Antioxid Redox Signal       Date:  2016-08-17       Impact factor: 8.401

5.  NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy.

Authors:  D S Bredt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

6.  The expression of neuronal nitric oxide synthase and dystrophin in rat regenerating muscles.

Authors:  Sachiko Hoshino; Norio Ohkoshi; Akiko Ishii; Shinichi Shoji
Journal:  J Muscle Res Cell Motil       Date:  2002       Impact factor: 2.698

Review 7.  Satellite cells and the muscle stem cell niche.

Authors:  Hang Yin; Feodor Price; Michael A Rudnicki
Journal:  Physiol Rev       Date:  2013-01       Impact factor: 37.312

8.  Muscle-specific AMPK β1β2-null mice display a myopathy due to loss of capillary density in nonpostural muscles.

Authors:  Melissa M Thomas; David C Wang; Donna M D'Souza; Matthew P Krause; Andrew S Layne; David S Criswell; Hayley M O'Neill; Michael K Connor; Judy E Anderson; Bruce E Kemp; Gregory R Steinberg; Thomas J Hawke
Journal:  FASEB J       Date:  2014-02-12       Impact factor: 5.191

9.  Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.

Authors:  Guy L Odom; Paul Gregorevic; James M Allen; Eric Finn; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

10.  HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.

Authors:  Claudia Colussi; Chiara Mozzetta; Aymone Gurtner; Barbara Illi; Jessica Rosati; Stefania Straino; Gianluca Ragone; Mario Pescatori; Germana Zaccagnini; Annalisa Antonini; Giulia Minetti; Fabio Martelli; Giulia Piaggio; Paola Gallinari; Christian Steinkuhler; Christian Steinkulher; Emilio Clementi; Carmela Dell'Aversana; Lucia Altucci; Antonello Mai; Maurizio C Capogrossi; Pier Lorenzo Puri; Carlo Gaetano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.